As of November 6, 2026, NewAmsterdam Pharma Co N.V. is a publicly traded company (Nasdaq: NAMS). The largest holder reporting an active stake on Schedule 13D is Frazier Life Sciences X, L.P., at 8.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Capital World Investors (10.4%), Fidelity (FMR) (10%) (Schedule 13D/A, September 22, 2026).
Is this your company?
About to sign with, pay or invest in NewAmsterdam Pharma Co N.V.? See the free Snapshot first.
Free to see. No signup.
Is NewAmsterdam Pharma Co N.V. a real, registered company?
- NewAmsterdam Pharma Co N.V. files with the SEC under CIK 1936258 (its SEC filings).
- Its shares are listed under the ticker NAMS on Nasdaq (also NAMSW) (SEC company record).
- Incorporated in P7; business address in Narrden, P7, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under NEWAMSTERDAM PHARMA COMPANY NV in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Robert W. Gunning (Form 8-K filed 2026-08-14). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are NewAmsterdam Pharma Co N.V.'s owners and officers?
NewAmsterdam Pharma Co N.V.: business address in Narrden, P7; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 10% |
| Schedule 13D/A, 2026-09-22 | Frazier Life Sciences X, L.P. | 8.7% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 8.8% |
| Schedule 13G/A, 2026-06-04 | Capital World Investors | 10.4% |
| Schedule 13D/A, 2026-05-14 | Bcls Ii Investco, LP | 1.76% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 7.6% |
| Schedule 13G/A, 2026-02-17 | Viking Global Investors LP | 3.7% |
| Schedule 13G, 2026-02-05 | Fmr LLC | 5.7% |
| Schedule 13D/A, 2025-12-04 | Bcls Ii Investco, LP | 4.7% |
| Schedule 13G/A, 2025-11-13 | Capital World Investors | 8.7% |
| Schedule 13D/A, 2025-11-07 | Bcls Ii Investco, LP | 9.99% |
| Schedule 13D/A, 2025-11-04 | Frazier Life Sciences X, L.P. | 7.7% |
Questions about who owns NewAmsterdam Pharma Co N.V.
Who owns NewAmsterdam Pharma Co N.V.?
On this page, 3 holders' latest ownership filings report 5% or more of NewAmsterdam Pharma Co N.V.: Capital World Investors (10.4%, Schedule 13G/A, filed 2026-06-04), Fmr LLC (10%, Schedule 13G/A, filed 2026-11-05) and Frazier Life Sciences X, L.P. (8.7%, Schedule 13D/A, filed 2026-09-22).
Who are the largest shareholders of NewAmsterdam Pharma Co N.V.?
By the share each holder's latest filing reports, the largest holders of NewAmsterdam Pharma Co N.V. on this page are Capital World Investors (10.4%), Fmr LLC (10%) and Frazier Life Sciences X, L.P. (8.7%).
When did Capital World Investors buy into NewAmsterdam Pharma Co N.V.?
The filings give report dates, not purchase dates. The earliest filing from Capital World Investors on this page is the Schedule 13G/A, filed 2025-11-13, reporting 8.7%; its latest, Schedule 13G/A filed 2026-06-04, reports 10.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on NewAmsterdam Pharma Co N.V.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on NewAmsterdam Pharma Co N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NewAmsterdam Pharma Co N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-08-14 | Robert W. Gunning | appointed |
Which insiders own NewAmsterdam Pharma Co N.V. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Forbion Growth Management B.V., a 10% owner: 10,656,172 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-02).
- Forbion IV Management B.V., a 10% owner: 10,656,172 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-02).
- Forbion Growth Opportunities Fund I Cooperatief U.A., a 10% owner: 10,656,172 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-02).
- ForGrowth NAP B.V., a 10% owner: 10,656,172 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-02).
- Forbion Capital Fund IV Cooperatief U.A., a 10% owner: 10,656,172 shares (8.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-01-02).
Shares outstanding: 119,929,998 as of 2026-11-02, from the company's latest SEC cover page.
How much has NewAmsterdam Pharma Co N.V. raised?
No fundraising or offering filing from NewAmsterdam Pharma Co N.V. is on file with us.
Keep reading
More on NewAmsterdam Pharma Co N.V. and the records around it.
NewAmsterdam Pharma Co N.V. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Aug 2026
Companies that share a holder
- Frazier Life Sciences X, L.P. also filed stake reports on 1 other company: Aspen Neuroscience, Inc. (Nov 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/newamsterdam-pharma-company-nv